Efficacy and Safety of Imatinib and Vinorelbine in Patients With Advanced Breast Cancer

Phase 4

Completed

• Conditions: Breast Cancer
• Interventions: Drug: Imatinib and Vinorelbine

• Registration Number: NCT00372476
• Lead Sponsor: Novartis Pharmaceuticals

Brief Summary

This study is designed to investigate the safety and efficacy of the combination of imatinib and vinorelbine in patients with advanced, anthracycline resistant breast cancer

Detailed Description

Not available

Study Timeline

• Study Start: 2006-06
• Study First Submitted: 2006-09-06
• Study First Submitted QC: 2006-09-06
• Study First Posted: 2006-09-07
• Primary Completion: 2012-07
• Study Completion: 2012-07
• Status Verified: 2017-02
• Last Update Submitted: 2017-02-03
• Last Update Posted: 2017-02-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 33

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Imatinib + Vinorelbine	Imatinib and Vinorelbine	-

Primary Outcome Measures

Name	Time	Method
Maximum tolerated dose (MTD)	at least 28 days

Trial Locations

Locations (1)

Novartis Investigative Site; 🇩🇪 Kiel, Germany